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Background: Sepsis is a serious medical condition requiring timely administered, appropriate antibiotic therapy.
Blood culture is regarded as the gold standard for aetiological diagnosis of sepsis, but it suffers from low sensitivity
and long turnaround time. Thus, nucleic acid amplification tests (NAATs) have emerged to shorten the time to
identification of causative microbes. The aim of the present study was to evaluate the clinical utility in everyday
practice in the emergency department of two commercial NAATs in patients suspected with sepsis.
Methods: During a six-week period, blood samples were collected consecutively from all adult patients admitted to the
general emergency department for suspicion of a community-onset sepsis and treated with intravenous antibiotics. Along
with conventional blood cultures, multiplex PCR (Magicplex™) was performed on whole blood specimens
whereas portions from blood culture bottles were used for analysis by microarray-based assay (Prove-it™).
The aetiological significance of identified organisms was determined by two infectious disease physicians
based on clinical presentation and expected pathogenicity.
Results: Among 382 episodes of suspected sepsis, clinically relevant microbes were detected by blood culture in 42
episodes (11%), by multiplex PCR in 37 episodes (9.7%), and by microarray in 32 episodes (8.4%). Although moderate
agreement with blood culture (kappa 0.50), the multiplex PCR added diagnostic value by timely detection of 15 clinically
relevant findings in blood culture-negative specimens. Results of the microarray corresponded very well to those of blood
culture (kappa 0.90), but were available just marginally prior to blood culture results.
Conclusions: The use of NAATs on whole blood specimens in adjunct to current culture-based methods provides a
clinical add-on value by allowing for detection of organisms missed by blood culture. However, the aetiological
significance of findings detected by NAATs should be interpreted with caution as the high analytical sensitivity
may add findings that do not necessarily corroborate with the clinical diagnosis.
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Sepsis is a major cause of morbidity and mortality in all
high income as well as middle and low income countries
[1-5]. About 20 million cases of sepsis are estimated to
occur each year around the world accounting for up to
135,000 deaths in Europe and 215,000 in the United
States [1,4]. Recent studies from different countries show* Correspondence: diana.karlsson@his.se
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unless otherwise stated.that the incidence of sepsis as well as the number of
sepsis-related deaths is continuously increasing [3,6-11].
At present, blood culture is considered the gold standard
for aetiological diagnosis in sepsis. Although blood culture
is associated with high specificity in species identification, it
is limited by a substantial time delay and low sensitivity, es-
pecially for slow-growing and fastidious organisms [12,13].
In an effort to address some of the limitations with blood
culture, nucleic acid amplification tests (NAATs) have beentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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to identification of microorganisms causing bacteraemia.
Several commercial multiplex assays, based on different
techniques such as conventional polymerase chain reac-
tion (PCR) (VYOO®, Analytik Gena, Germany), real-time
PCR (Magicplex™ Sepsis Real-time Test, Seegene, Korea;
LightCycler® SeptiFast, Roche, Switzerland; Sepsitest™,
Molzym, Germany) and microarray (Prove-it™ Sepsis,
Mobidiag, Finland) are now on the market. These as-
says have been tested in several studies [14-24] but
rarely is there a clinical validation of the results.
The aim of this population-based study was therefore
to evaluate the clinical utility of two commercial NAATs,
Magicplex™ Sepsis Real-time Test and Prove-it™ Sepsis,
in patients with suspected sepsis. Magicplex™ Sepsis
Real-time Test is a PCR-based test screening for 73 spe-
cies of Gram positive bacteria, twelve species of Gram
negative, and six species of fungi and three resistance
genes (mecA, vanA, and vanB) directly in whole blood
samples. The microarray-based assay called Prove-it™
Sepsis combines genome amplification by conventional
PCR and microarray technology for simultaneous identi-
fication of over 60 bacterial pathogens, and 13 fungal
pathogens, and three resistance genes (mecA, vanA, and
vanB) in positive blood cultures.Methods
Patients and specimens
From September 2011 to June 2012, a prospective obser-
vational study of the incidence of community-onset se-
vere sepsis and septic shock in adults was conducted at
Skaraborg Hospital, in the western region of Sweden.
During a limited period of the prospective study, from
February to April 2012, NAATs were performed as part
of routine patient care in addition to blood culture in all
patients >18 years admitted to the emergency depart-
ment for suspicion of community-onset sepsis. All pa-
tients received oral and written information about the
study. In patients suspected to have sepsis or severe sep-
sis, it is mandatory to rapidly make appropriate sampling
for microbiological diagnosis before antibiotic treatment
is instituted. This microbiological testing, using appro-
priate and approved tests, needed no patient consent ac-
cording to the Swedish Law. The diagnostic tests were
made upon arrival to the emergency department and no
additional sampling was made. Some patients were too
sick and/or died within 24 hours and could never give
an informed consent. Those patients who could not give
an informed consent, were evaluated anonymously, only
for diagnosis and results of commercially available tests
used for diagnostic purposes of the suspected sepsis. The
Regional Ethics Committee in Gothenburg (no. 376–11)
approved the study and the consent process.Blood culture
In this study, an episode was defined as each separate case
of clinically suspected community-onset sepsis treated with
intravenous antibiotics. Only one episode per patient and
admission were included in the final data analysis to avoid
bias. For each episode, two sets of blood cultures from two
different puncture sites were collected before administra-
tion of the first dose of intravenous antibiotics. However,
for a few episodes, due to feasibility, only one set of blood
culture was collected. Blood cultures were conducted in
BacT/ALERT® FN (bioMérieux, France). Typing and defin-
ite species identification with MALDI-TOF MS was per-
formed on a Microflex LT mass spectrometer (Bruker
Daltonics, United States) with BioTyper software v2.0 using
default parameter settings. Spectral scores above 2.0 were
used as cut-off for correct identification. Antibiotic suscep-
tibility was determined by accredited laboratory methods
according to EUCAST guidelines (www.eucast.org).
Multiplex PCR assay
The test procedure for Magicplex™ was performed on 1 mL
fresh whole blood (EDTA) collected before administration of
antibiotics and not older than 24 hours. DNA extraction
from whole blood was performed using the SelectNA Blood
Pathogen Kit (Molzym, Germany). The first steps of the ex-
traction, lysis of human cells and digestion of human DNA,
were manually performed according to the manufacturer’s
instructions. Pure bacterial/fungal DNA was then extracted
automatically from the prelysed samples on the instrument
Nordiag Arrow/Liaison IXT (DiaSorin, Italy). The first PCR,
producing amplicon banks, was performed using the kit
Magicplex Sepsis Amplification on a GeneAmp PCR System
9700 (Applied Biosystems, United States). Real-time PCR
was then performed with the Magicplex Screening Real-time
Detection Kit on a CFX96 (Bio-Rad, United States). The
screening revealed the presence of Gram positive or Gram
negative bacteria, drug resistance genes or fungi. Species
identification was performed with the Magicplex ID 1-ID 9
Real-time Detection Kit on samples that became positive in
the screening step. All PCR-reactions were set up in a UV-
box according to the recommendations from the manufac-
turer. The dedicated software Seegene viewer was used to in-
terpret the analysis data, where the result from every sample
is presented in a table as Detected or Not detected. A whole
process control was included in the assay. If this was valid,
the assay result could be interpreted.
Microarray-based assay
Prove-it™ was performed on aliquots derived from blood cul-
ture bottles removed from the automated blood culture sys-
tem. After removal, the bottles were stored in 4°C between
1–2 days until DNA extraction was performed. For each epi-
sode, aliquots were taken from that pair of blood culture
bottles, one aerobic and one anaerobic bottle, derived from
Table 1 Schematic distribution of microorganisms
according to expected pathogenic potential
True pathogens Possible pathogens
Bacteroides fragilis group Aerococcus spp.
Candida spp. Anaerobic Gram positive cocci
Clostridium spp. other than C.
perfringens
Lactobacillus spp.
Enterobacteriaceae spp. Non-fermenting Gram negative rods




Haemophilus spp. Commensals (common
contaminants)aHACEK group
Listeria spp. Bacillus spp.
Mycobacterium spp. Coagulase-negative staphylococci
Neisseria spp. Corynebacterium spp.









Streptococcus group A, B, C, G
Streptococcus pneumoniae
aHACEK group includes: Haemophilus parainfluenzae, Haemophilus aphrophilus,
Haemophilus paraphropilus, Actinobacillus actinomycetemcomitans, Aggregatibacter
aphrophiuls, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae.
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from each bottle. Regardless if the blood culture bottles were
found positive or negative, sample volumes from each pair
of bottles was pooled together prior to DNA extraction.
DNA was extracted using 400 μL of sample volume and
eluted in a final volume of 200 μL using a MagNA Pure
Nucleic Acid Isolation Kit I on a MagNAPure Compact
System (Roche Applied Science, Switzerland). The proced-
ure for the microarray assay was performed according to
protocols provided by the manufacturer. Briefly, both a bac-
terial and a fungal PCR master mix were prepared. The PCR
reactions were set up in a laminar airflow bench where no
amplified PCR products were handled. After PCR amplifica-
tion, the bacterial PCR product and the fungal PCR product
derived from the same episode were added to the same well
of the microarray. Subsequently, hybridization and staining
procedures were performed. For detection and analysis of
the samples, the dedicated software Prove-it™ Advisor was
used. Based on the outcomes of several built-in controls, the
software evaluated whether the performance of the assay is
acceptable. All analysis parameters were adjusted automatic-
ally without any manual involvement.
Data interpretation and statistical analysis
All records of the patients and microbial findings were
assessed by two senior physicians in infectious diseases
(LL and GJ). The clinical judgment was based on the pa-
tient history with special reference to sudden onset of
fever, rigors, gastrointestinal symptoms, tachypnea, men-
tal confusion, pain out of proportion, and muscle weak-
ness. Physical examination was done with attention to
blood pressure <90 mm Hg, respiratory rate >20/min,
and oxygen saturation <90%. Standard biomarkers
included serum lactate, leucocyte cell count, neutrophil-
lymphocyte count ratio, and C-reactive protein. Judg-
ment was also based on imaging and microbiological
testing of suspected infectious foci including culture,
PCR, and antigen test, apart from the NAAT assays
described in detail above.
It remains challenging to determine the aetiological signifi-
cance of organisms detected in blood. This applies especially
to NAATs, but also to conventional blood culture although
to a lesser degree. In this study, decisions of aetiological sig-
nificance of detected organisms were made based on
expected pathogenicity (Table 1) and clinical presentation as
previously described [25,26]. Detected organisms were inter-
preted as clinically relevant, of unknown significance or con-
taminant according to the algorithm described in Figure 1.
Organisms detected only by a NAAT were also regarded as
clinically relevant, but with more stringent criteria than posi-
tive blood culture results. Microorganisms of unknown
aetiological significance are findings considered not consist-
ent with the clinical diagnosis having no implications for
the medical management of the patients. However, linksbetween the microorganism and the medical condition of
the patient cannot be excluded.
McNemar’s test was conducted for comparing proportions
in paired samples, whereas z test was performed for compar-
ing proportions in independent samples. A two-sided p value
of <0.05 was considered statistically significant. Concor-
dances between blood culture and NAATs were tested with
kappa statistics for inter-rater agreement; cut-off values for
the kappa value have been described elsewhere; 0.41-0.60 are
considered of moderate agreement, and those of 0.81-1.00 of
very good agreement [27]. Statistical analyses were per-
formed using Matlab v. 7.10 (The Mathworks, Inc., United
States).Results
A total of 375 patients entered this study. Eight patients
were admitted twice during the study period, resulting
in a total of 383 episodes analysed with blood culture
and both NAATs. For the multiplex PCR, the whole
Figure 1 Algorithm for deciding on clinical relevance of microbial findings in blood by blood culture [25] or NAAT. Other cultures were made
from clinically relevant sites before administration of intravenous antibiotics. On suspicion of pneumonia or sepsis with unknown focus, a pulmonary X-ray
was performed. Ultrasound, computed tomography scan, and magnetic resonance imaging were used when deemed necessary for diagnosing the site
of infection. BC blood culture; NAAT nucleic acid amplification test.
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of the 383 blood samples initially tested. These samples
were retested on a ten-fold dilution of the extracted DNA.
After the re-run, one sample did still not give a final result
and was excluded from further analysis, making a total of
382 episodes.
At least one microorganism was detected in 138 episodes
by either method. Microorganisms defined as commensals
(Table 1) were considered to be contaminants and excluded
from analysis if only found on a single occasion regardless
of detection method. In total, 89 clinically relevant findings
or findings of unknown significance were identified in 77
episodes (20%). A detailed description including clinical
comments for these findings can be found in Additional file
1. In eight episodes, a clinically relevant finding was de-
tected by blood culture in a bottle not included in that pair
of bottles from which aliquots for the microarray analysis
was derived. Thus, these eight episodes were excluded from
the analysis of the microarray results.
For blood culture, the result of species identification
was usually available 6–7 hours after a bottle has flagged
positive (Figure 2). The turnaround time for the multi-
plex PCR assay was estimated to around seven hours.
For the microarray, the turnaround time from positive
blood culture bottle to species identification was ap-
proximately four hours. The diagnostic performance for
blood culture and the NAATs are shown in Table 2.Multiplex PCR assay
The rate of episode positivity for multiplex PCR was
14% (53/382), whereas the rate of episode positivity for
blood culture was 11% (42/382, p = 0.61). Cohen’s kappa
coefficient for agreement between the results of multi-
plex PCR and blood culture was 0.52 (95% CI 0.37-0.66).
In total, 37 clinically relevant findings in 37 episodes
and 23 findings of unknown significance in 21 episodes
were detected by multiplex PCR. For blood culture, 44
findings in 42 episodes were clinically relevant and one
finding of unknown significance. The multiplex PCR and
blood culture results agreed for 22 clinically relevant
findings (Figure 3A). Multiplex PCR missed 22 clinically
relevant findings in 20 episodes and one finding of un-
known significance. On the other hand, 38 findings iden-
tified by multiplex PCR in 35 episodes were not detected
by blood culture. Fifteen of these 38 findings were con-
sidered as clinically relevant; five of these 15 findings
were considered as proven aetiology of the infections
since the same bacteria were found by culture from the
site of infection (Table 3). The remaining ten findings
made by multiplex PCR were negative in blood culture
and other diagnostic tests, but consistent with the clinical
diagnosis and therefore regarded as clinically relevant
(Table 3). Twenty-three of the 38 findings detected by
multiplex PCR but not by blood culture were regarded to
be of unknown significance. Ten were findings of Gram
Figure 2 Workflows and turnaround times for the detection methods used in the present study.
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bacteria and two were findings of Candida species
(Table 4).Microarray-based assay
The rate of episode positivity for the microarray assay was
8.4% (32/382) and for blood culture 8.9% (34/382, p = 0.37).
Cohen kappa statistic for agreement between the results of
microarray and blood culture was 0.92 (95% CI 0.84-0.99).Table 2 Diagnostic performance of blood culture, multiplex P
Sensitivity Specificity
(95% CI) (95% CI)
Blood culture 72% (61–84) 99% (99–100)
Multiplex PCR 64% (51–76) 96% (93–98)
Microarray 62% (49–75) 99% (97–100)
NPV negative predictive value; PPV positive predictive value.
aFor each method, all episodes were classified according following criteria: i) true p
positive - episode positive only for finding(s) of unknown significance; iii) false nega
relevant finding detected by another method; iv) true negative - episode negative w
any method.In total, 32 clinically relevant findings in 31 episodes
and five findings of unknown significance in five epi-
sodes were detected by microarray. The results between
microarray and blood culture showed concordance for
30 clinically relevant findings (Figure 3B). The micro-
array failed to detect four clinically relevant findings de-
tected by blood culture. However, two of these findings
belonged to species not covered by the microarray panel
(Streptococcus anginosus and Streptococcus group G).
The microarray identified one clinically relevant findingCR, and microarraya
PPV NPV Accuracy
(95% CI) (95% CI) (95% CI)
98% (93–100) 94% (92–97) 95% (92–97)
73% (60–85) 94% (91–96) 91% (88–94)
86% (75–97) 95% (92–97) 94% (91–96)
ositive – episode positive for at least one clinically relevant finding; ii) false
tive - episode negative with the method, but positive for at least one clinically





by BC and multiplex 
PCR
(n = 23)
Positive by multiplex  
PCR only (n = 112)








by BC and microarray
(n = 37)
Positive by microarray
only (n = 14)










Figure 3 Microbial concordances between blood culture and NAATs. A Number of microbes detected by blood culture and/or multiplex PCR. B Number
of microbes detected by blood culture and/or microarray. BC blood culture; CRF clinically relevant finding; CNRF clinically not relevant finding; OUS finding
of unknown significance.
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by either blood culture or multiplex PCR (Table 5).
Discussion
The focus of this study is on the clinical utility of two
commercial NAATs in the aetiological diagnosis of pa-
tients with suspected sepsis. We found that the multi-
plex PCR assay added diagnostic value by timely
detection of clinically relevant microbes missed by blood
culture. The results of the microarray-based assay corre-
sponded well to those of blood culture, but its clinical
utility is reduced by the prerequisite of time-consuming
cultivation.
Currently, blood culture is considered the gold standard
for aetiological diagnosis of sepsis although it suffers from
having a low sensitivity. It can only detect viable microor-
ganisms, and the medium is not optimized for culturing
fungi and fastidious bacteria. Thus, blood culture can be
considered to be a poor gold standard, which implies diffi-
culties in evaluating novel sepsis tests since no other la-
boratory reference standard for sepsis diagnosis exists. For
that reason, different reference standards have been used in
studies assessing sepsis tests. Some have used blood culture
results alone as gold standard [20,28], whereas others have
considered all pathogenic findings detected by any method
[16,29]. We assessed the performances of blood culture and
the two NAATs by classifying all findings judged as
clinically relevant as “true positives”. The diagnostic
sensitivity for multiplex PCR (64%, Table 2) was com-
parable with the rate in a similar study by Carrara et al.
(65%, p = 0.91) [16], as well as the specificity (96% vs.
92%, p = 0.05) [16]. However, Loonen et al. havereported significantly lower sensitivity (37%, p < 0.001)
and specificity (77%, p = 0.0001) for Magicplex™ [19].
For the microarray assay, we observed a significantly
lower diagnostic sensitivity (62% vs. 96%, p < 0.0001,
Table 2) whereas the specificity was equal (99% vs. 99%,
p = 1.0) compared with a previous study [20]. The use
of different gold standards and study populations may
explain observed differences in the performance char-
acteristics [16,19,20,30].
Although the multiplex PCR assay could not detect all
clinically relevant microbes, it offered added diagnostic
value by the detection of several important pathogens not
detected by the conventional culture-based method
(Table 3). Consequently, the concordance between the re-
sults of blood culture and multiplex PCR assay is moderate
(kappa 0.50) (Table 2), whereas the microarray results
showed a high degree of agreement with the results of
blood culture (kappa 0.90) (Table 2). These results could be
expected since the microarray assay is performed on ali-
quots derived from blood culture bottles, whereas the
multiplex PCR is performed on microbial DNA extracted
from a different whole blood sample than the cultured
portion.
A remarkable finding is that multiplex PCR of only
1 mL whole blood reached a sensitivity of 64% compared
to 72% for culture using 32–40 mL blood, despite more
stringent criteria for clinical relevance in the PCR case.
However, both methods failed to detect a number of
sepsis cases. From a strictly quantitative aspect, the de-
tection level for microorganisms in blood samples at a
given time, the diagnostic sensitivity, is depending on
the concentration of microorganisms and the volume
Table 4 Microbial findings of unknown significance made
by multiplex PCR but not by blood culture
Patient Multiplex PCR results Clinical diagnosis
1 Acinetobacter baumannii Acute pyelonephritis due to E.
coli.
2 Acinetobacter baumannii Infected chronic leg ulcer. A.




Infected chronic leg ulcers.
4 Acinetobacter baumannii Pulmonary embolism.
5 Candida krusei Pneumonia verified by chest
X-ray.
6 Candida parapsilosis Acute pyelonephritis due to E.
coli.
7 Enterobacter cloacae Polycytemia vera. Fever and
respiratory distress. Believed to
have an adverse reaction to
hydroxyurea.
Infiltrate on chest X-ray. PCR
from nasopharynx positive for
human metapneumovirus and
coronavirus.
8 Enterococcus faecalis Acute pyelonephritis due to E.
coli.
9 Enterococcus gallinarium Nausea. No other diagnosis was
made.
10 Escherichia coli Acute otitis media. No other
cultures were positive.
11 Klebsiella oxytoca S. aureus endocarditis.
12 Klebsiella pneumoniae Acute vomiting and fever. No
other diagnosis was made.




Influenza A verified by PCR.
15 Staphylococcus aureus Pneumonia due to K. pneumoniae.
Lymphoma.




Pulmonary fibrosis and suspected
pneumonia.
18 Streptococcus agalactiae Arrived with severe sepsis.
Diseased within 24 hours.
19 Streptococcus pneumoniae Acute diabetic ketoacidosis. PCR
from nasopharynx positive for
human rhinovirus. Highly elevated
neutrophil count.
20 Streptococcus pneumoniae Acute pyelonephritis due to E.
coli.
21 Streptococcus spp. Goiter.
aTwo microbial findings of unknown significance in the same patient.
Table 3 Clinically relevant microbial findings made by









Acute pyelonephritis. Grew E. faecalis in
the urine.
3 Escherichia colia Acute pyelonephritis. Grew E. faecalis in
the urine.
4 Escherichia colia Acute pyelonephritis. Grew E. faecalis in
the urine.
5 Escherichia colia Acute pyelonephritis. Grew E. faecalis in
the urine.
6 Escherichia coli Acute cholecystitis. Elevated liver enzymes
and positive computed tomography scan.
Three months earlier, the patient had an
acute cholecystitis with E. coli in blood
cultures.
7 Escherichia coli Acute pyelonephritis. Urine culture could
not be obtained.
8 Escherichia coli Abdominal abscess after appendectomy.
9 Klebsiella oxytoca Perianal abscess.
10 Klebsiella
pneumoniae








Infected chronic leg ulcer.
13 Streptococcus
pneumoniae




Fever, respiratory distress, pulmonary
fibrosis. No other diagnosis was made.
Chest x-ray inconclusive for
pneumonia.
15 Streptococcus spp. Acute cholangitis. Elevated liver enzymes
and positive computed tomography scan.
aConsidered as proven aetiology since the same species were found by culture
from the site of infection.
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time is not known. In bacteraemia, an average concentration
of 0.25 CFU/mL blood was reported by Arpi et al. [31].
Jonsson et al. [32] theoretically calculated the probability of
detecting bacteria as a function of the concentration in
blood and found empirically by blood culture that 29% of all
cases with Escherichia coli and 18% of S. aureus bacteraemia
had a most probable concentration of only 0.036 CFU/mL.
The gain in yield of microorganisms by increasing the vol-
ume of cultured blood in more modern automated culture
systems was emphasized by Cockerhill et al. [33] and Lee
et al. [34]. To obtain a >99% sensitivity with these systems,
four blood cultures, each involving 20 mL is needed [34].
The gain is probably due to the detection of the most mi-
nute concentrations, either by enhanced culture systems or
overcoming the effects of early antibiotic therapy by resins.NAATs introduced to diagnose sepsis by sampling
blood may add new information implying higher analytical
sensitivity. By definition, the analytical sensitivity of an
assay refers to the smallest value of the analyte that can
Table 5 Microbial findings made by microarray but not
by blood culture
Patient Microarray results Clinical diagnosis
1 Enterobacter cloacaeb Tendinitis of the hand due to S.
aureus.
2 Enterobacter cloacaeb Acute pyelonephritis due to E. faecalis.
3 Enterobacter cloacaeb Neutropenic fever.
4 Enterococcus faecalisa Acute bronchitis. E. faecalis in urine.
5 Staphylococcus aureusb Pneumonia.
6 Staphylococcus aureusb Acute pyelonephritis due to E. coli.
aClinically relevant microbial finding.
bMicrobial finding of unknown significance.
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not synonymous with the diagnostic sensitivity. A sin-
gle bacterial cell is obviously the smallest theoretical
unit that can be applied for blood culture or culture in
a wider sense. With NAATs, a single bacterial cell, dead
or alive, may contain multiples of a certain target se-
quence, e.g., in bacteria the conserved 16S rRNA gene
sequence is often used as PCR template due to its high
copy number in each cell. The downside of using detec-
tion methods with high analytical sensitivity, such as
PCR, is the increased number of findings of unknown
significance as well as contaminants. We then have to
cope with unexpected microbial findings that do not
necessarily corroborate with the clinical picture, as
translocation of bacteria and fungi over the mucosal
gut barrier in patients with malignancies or on paren-
teral nutrition is an increasing diagnostic dilemma.
Thus, we are urged to tighten the communication be-
tween the laboratory and the clinicians to organise, as-
semble and critically review the unexpected findings.
There is also a qualitative aspect. Certain species
seem to correlate better with genuine sepsis than
others, i.e., Enterobacteriaceae spp. and pneumococci
[35]. The detection of identical microorganisms from
multiple sampling sites or occasions is another genu-
ine marker for true bacteraemia. This further implies
that a single finding of a microbe with one detection
system, e.g., culture, may move the interpretation from
probable to proven if the same finding is done with
e.g., PCR. However, true bacteraemia also occurs in pa-
tients void of an inflammatory response. This shall not
be regarded as a benign finding until the following fac-
tors are ruled out. First, translocation of bacteria from
the gut to the bloodstream may occur in patients with mal-
functioning mucosal barriers. Well known examples are E.
cloacae (occult malignancy) [35], Streptococcus group G,
i.e., Streptococcus dysgalactiae subsp. equisimilis (haemato-
logical malignancy and solid tumours) [36], and the former
Streptococcus bovis group, i.e., S. gallolyticus subsp. gallo-
lyticus and subsp. pasteurianus (colonic cancer), and S.infantarius (cancer of the bile tree or pancreas) [37]. Ex-
perimental work on animals showed an increased risk for
bacterial translocation for subjects fed exclusively by the
parenteral route [38]. Finally, there are a large number of
conditions linked to immunodeficiencies where both muco-
sal barriers and normal inflammatory response are mal-
functioning. A significant microbial finding, e.g., single
detection of a species with significant pathogenic profile
or multiple detection of the same but low-pathogenic spe-
cies, should alert the clinician independent of clinical signs
of sepsis and whether the detection method was culture or
molecular. Combining the methods might therefore pro-
vide important clinical information concerning not only the
acute infection but also underlying conditions.
In our laboratory, it usually takes around 6–7 hours after
a blood culture bottle has flagged positive before the isolate
has grown enough on the plates enabling species identifica-
tion within minutes by MALDI-TOF MS (Figure 2). At the
same time a primary reading of the antibiogram is done
and aids to disclose resistant strains of Staphylococcus aur-
eus, Enterobacteriaceae spp. and non-fermenters. However,
the time needed for species identification by conventional
culture-based methods differs between clinical laboratories
depending on routines. For the microarray, the turnaround
time from positive bottle to microorganism identification
was about four hours including preparation of blood cul-
ture bottles and DNA extraction. We estimated that the
use of the microarray would save 2–3 hours compared to
routine methods, but it is more labour intensive. For both
blood culture and microarray, the incubation time of typic-
ally 1–3 days must also be considered. However, a time sav-
ing was obtained using multiplex PCR with an estimated
turnaround time of only seven hours since this assay was
performed directly on whole blood sample requiring no in-
cubation time.
For the multiplex PCR assay, the whole process control
was invalid or partially invalid in 45 (12%) of the 383 blood
samples initially tested. According to the manufacturer, the
whole process control indicates whether the process has
functioned optimally or not. No further information is
given when the whole process control is flagged as invalid.
We speculated that a very high DNA concentration in the
samples either inhibited the PCR reaction or the purifica-
tion process. Therefore, these samples were retested on a
ten-fold dilution of the extracted DNA and all but one sam-
ple then gave a final result. The high rate of invalid whole
process control thus reduces the clinical utility of multiplex
PCR since such samples need to be retested.
Our study has several limitations. One of the most im-
portant is that TATs were not precisely measured, just
roughly estimated, mainly due to handling procedures. In
addition, none of the NAATs were run 24/7; multiplex PCR
was performed once daily whereas the microarray was ran
every second day.
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Our results indicate that the use of multiplex PCR as-
says on whole blood specimens may shorten the time
to identifying causative agents in blood. As for the
microarray-based assay, it corresponds well to blood
culture, but the prerequisite of time-consuming cultiva-
tion reduces its clinical utility. Most important, we
found that the multiplex PCR assay has the potential to
serve as a complement to blood culture in detecting
clinically relevant microbes in blood. However, it should be
stressed that the aetiological significance of findings de-
tected by PCR-based assays should be interpreted with cau-
tion as the high analytical sensitivity may add findings that
do not necessarily corroborate with the clinical diagnosis.
Improving PCR technology, e.g., repeated sampling or in-
creasing diagnostic sensitivity by processing a larger volume
of blood, by faster and automated analysis will make
NAATs a better tool for diagnosing septic patients.
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